Your doctor will manage you according to the requirements of the RISK MANAGEMENT PROGRAMME to ensure that you take POMARZA in a safe manner. Do not take POMARZA if:
WARNING: BLOOD CLOTS IN VEINS AND ARTERIES (VENOUS THROMBOEMBOLISM)
Deep Venous Thrombosis (blood clots in the veins and arteries) and Pulmonary Embolism (blood clots in the lungs) occur in patients with multiple myeloma treated with POMARZA. Your doctor may prescribe other medicines to prevent this from happening after assessing your risk factors (see “Take special care with POMARZA”).
• you are allergic (hypersensitive) to pomalidomide or to any of the other ingredients of POMARZA listed in section 6.
• you are pregnant or think you may be pregnant or are planning to become pregnant, as POMARZA is expected to be harmful to an unborn child (see ‘Take special care with POMARZA’ and ‘Pregnancy, breastfeeding and fertility’).
• you are able to become pregnant and you are not using or are not able to use effective contraceptive measures to prevent pregnancy (see ‘Take special care with POMARZA’ and ‘Pregnancy, breastfeeding and fertility’) and as outlined in the RISK MANAGEMENT PROGRAMME.
• you are a male patient and you are not able to follow or comply with the required contraceptive measures (see ‘Take special care with POMARZA’ and ‘Pregnancy, breastfeeding and fertility’).
If you are uncertain whether any of the conditions above apply to you, talk to your doctor, pharmacist or nurse before taking POMARZA.
Warnings and precautions
Take special care with POMARZA in the following situations:
For women taking POMARZA Before starting your treatment, you should ask your doctor if you are able to become pregnant, even if you think this is unlikely. If you are able to become pregnant:
- you will have pregnancy tests under the supervision of your doctor (before treatment, every 4 weeks during treatment, and 4 weeks after the treatment has finished).
- you must use two effective methods of contraception for 4 weeks before starting treatment, during treatment including dose interruptions and until 4 weeks after stopping treatment. Your doctor will advise you on appropriate methods of contraception.
If you become pregnant despite the prevention measures:
- you must stop the treatment immediately and talk to your doctor straight away.
For men taking POMARZA POMARZA passes into human semen. If your female partner is pregnant or able to become pregnant, you must use condoms during treatment including dose interruptions and for 4 weeks after the end of treatment (even if you have undergone vasectomy). Male patients taking POMARZA should not donate sperm or semen during treatment including dose interruptions and for 4 weeks following the end of treatment.
All patients:
- if you have ever had blood clots in the past, during the treatment with POMARZA you have an increased risk of getting blood clots in your veins and arteries. Your doctor may recommend that you take additional treatments (e.g. warfarin) or lower the dose of POMARZA to reduce the chance of you getting blood clots.
- if you have ever had an allergic reaction such as rash, itching, swelling, feeling dizzy or trouble breathing while taking related medicines called ‘thalidomide’ or ‘lenalidomide’, you may have an increased risk of an allergic reaction to POMARZA. Talk to your doctor, pharmacist or nurse before taking POMARZA.
- if you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the blood which can lead to kidney failure. You may also experience an uneven heartbeat. This condition is called tumour lysis syndrome.
- if you see signs of bleeding, including nose bleeds.
- if you suffer from thyroid conditions (underactive thyroid).
- if you suffer from heart conditions, or have had previous problems with your heart.
- if you experience any problems with your lung, e.g., difficulty in breathing.
- your doctor will monitor your liver function while you are taking POMARZA.
- there may be an increased risk of infections while you are using POMARZA. Please notify your doctor if you feel ill or have a fever.
You may feel dizzy or experience fatigue or confusion while you are using POMARZA.
If you experience new or worsening neurological, cognitive or behavioural signs or symptoms, your doctor may need to evaluate you for Progressive multifocal leukoencephalopathy (PML). It is important to take into consideration that patients with multiple myeloma being treated with POMARZA may develop additional types of cancer, therefore your doctor should carefully evaluate the benefit and risk when you are prescribed POMARZA.
Blood donation and blood tests You should not donate blood during treatment and for 4 weeks after the end of treatment. Before and during the treatment with POMARZA you will have regular blood tests. This is because POMARZA may cause a fall in the number of blood cells that help fight infection (white cells) and in the number of cells that help to stop bleeding (platelets). Your doctor should ask you to have a blood test:
- before treatment
- every week for the first 8 weeks of treatment
- at least every month after that for as long as you are taking POMARZA
As a result of these tests, your doctor may change your dose of POMARZA or stop your treatment. The doctor may also change the dose or stop the medicine because of your general health.
At the end of the treatment, you should return all unused capsules to the pharmacist.
Children and adolescents
POMARZA is not to be taken by children below the age of 18 years.
Other medicines and POMARZA
Always tell your healthcare provider if you are taking any other medicine. (This includes complementary or traditional medicines). Tell your doctor if you are taking any of the following medicines:
- some medicines used to treat fungal infections such as ketoconazole.
- certain anti-depressants such as fluvoxamine.